Mayne Pharma Group (ASX:MYX) said that it has been served with a legal proceeding filed in the US District Court of Delaware against its US unit, Mayne Pharma, according to a Friday filing with the Australian bourse.
The lawsuit filed by US-based women's healthcare company TherapeuticsMD (TXMD) alleges breach of contract, fraudulent inducement, and unjust enrichment related to the 2022 transaction agreement between the companies, the filing said.
The company plans to vigorously defend the case, which it believes is without merit, the filing added.
MYX also stated it had separate claims against TXMD, alleging damages exceeding TXMD's claims.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。